Wakayama Mariko, Abei Masato, Kawashima Rei, Seo Emiko, Fukuda Kuniaki, Ugai Hideo, Murata Takehide, Tanaka Naomi, Hyodo Ichinosuke, Hamada Hirofumi, Yokoyama Kazunari K
Division of Gastroenterology, University of Tsukuba Graduate School of Comprehensive Human Sciences, Tsukuba, Ibaraki, Japan.
Clin Cancer Res. 2007 May 15;13(10):3043-50. doi: 10.1158/1078-0432.CCR-06-2103.
Cancers of biliary system represent highly malignant diseases of dismal prognosis. We have previously introduced AxdAdB3, an E1A, E1B double-restricted oncolytic adenovirus, which showed excellent oncolytic efficacy for approximately half of the biliary cancer lines with an enhanced safety to normal cells. The purpose of this study was to evaluate whether RGD-fiber modification (AxdAdB3-F/RGD), which enables integrin-dependent infection, can improve the infectivity and efficacy of AxdAdB3 for biliary cancers.
Expressions of adenoviral receptors, coxsackievirus adenovirus receptor (CAR) and integrins (alpha(v)beta(3) and alpha(v)beta(5)), were compared with the level of infectivity of LacZ-expressing replication-defective adenoviruses with wild-type fibers or RGD-modified fibers in a panel of biliary cancer cell lines in vitro. Viral replication and cytotoxicity in vitro of AxdAdB3-F/RGD, a novel E1A, E1B double-restricted replication-selective adenovirus with RGD-modified fibers, were compared with those of its parent virus, AxdAdB3, in various biliary cancer cells and in normal cells. In vivo antitumor effects of these oncolytic viruses were compared in a xenograft tumor model.
Expression of CAR significantly correlated with the adenovirus infectivity, whereas integrin alpha(v)beta(5) was abundantly expressed in almost all biliary cancer cells. Whereas AxdAdB3 effectively replicated and lysed only the biliary cancer cells with a preserved expression of CAR, AxdAdB3-F/RGD exhibited efficient replication and potent oncolysis in both CAR-positive and CAR-negative biliary cancer cells. AxdAdB3-F/RGD showed attenuated replication and little cytopathy in human normal cells (i.e., hepatocytes, WI-38 cells) as well as AxdAdB3. Furthermore, in nude mice with s.c. xenografts of CAR-deficient human biliary cancer, i.t. AxdAdB3-F/RGD therapy caused a marked inhibition of tumor growth.
The RGD-fiber modification strategy enhanced the infectivity, replication, and oncolytic effects of the E1A, E1B double-restricted oncolytic adenovirus for CAR-deficient biliary cancers. In addition, it preserved the merit of excellent safety of the double-restricted virus for normal cells. These results suggest a potential use of this agent for the treatment of biliary cancers.
胆道系统癌症是预后极差的高度恶性疾病。我们之前已引入AxdAdB3,一种E1A、E1B双限制溶瘤腺病毒,它对大约一半的胆管癌细胞系显示出优异的溶瘤效果,且对正常细胞的安全性增强。本研究的目的是评估RGD纤维修饰(AxdAdB3 - F/RGD),即实现整合素依赖性感染,是否能提高AxdAdB3对胆管癌的感染性和疗效。
在一组胆管癌细胞系中,将腺病毒受体、柯萨奇病毒腺病毒受体(CAR)和整合素(α(v)β(3)和α(v)β(5))的表达与携带野生型纤维或RGD修饰纤维的表达LacZ的复制缺陷型腺病毒的感染性水平进行比较。将新型具有RGD修饰纤维的E1A、E1B双限制复制选择性腺病毒AxdAdB3 - F/RGD与其亲本病毒AxdAdB3在各种胆管癌细胞和正常细胞中的体外病毒复制和细胞毒性进行比较。在异种移植瘤模型中比较这些溶瘤病毒的体内抗肿瘤作用。
CAR的表达与腺病毒感染性显著相关,而整合素α(v)β(5)在几乎所有胆管癌细胞中大量表达。虽然AxdAdB3仅在保留CAR表达的胆管癌细胞中有效复制并裂解,但AxdAdB3 - F/RGD在CAR阳性和CAR阴性胆管癌细胞中均表现出高效复制和强效溶瘤作用。AxdAdB3 - F/RGD在人正常细胞(即肝细胞、WI - 38细胞)中以及AxdAdB3一样,复制减弱且几乎没有细胞病变。此外,在皮下接种了CAR缺陷型人胆管癌异种移植瘤的裸鼠中,瘤内注射AxdAdB3 - F/RGD疗法显著抑制了肿瘤生长。
RGD纤维修饰策略增强了E1A、E1B双限制溶瘤腺病毒对CAR缺陷型胆管癌的感染性、复制和溶瘤作用。此外,它保留了双限制病毒对正常细胞安全性优异的优点。这些结果表明该药物在治疗胆管癌方面具有潜在用途。